Literature DB >> 6727439

Influence of age-related changes in rodent liver morphology and physiology on drug metabolism--a review.

C F van Bezooijen.   

Abstract

Age-related changes in weight, morphology and physiology of the rodent liver influencing hepatic drug metabolism are reviewed. Next to the changes in liver weight/body weight ratio with age, the spontaneous occurrence of neoplastic and non-neoplastic lesions may be of particular importance. In addition, the decrease in liver blood blow with age diminishes the biotransformation capacity of the total liver. However, the albumin concentration in plasma and drug uptake do not play important roles, since they are unchanged or only slightly lower in old rats or mice. Drugs are generally metabolized by the liver in two phases: the so-called phase I and phase II metabolism. For most drugs, the phase I reaction is an oxidation. This reaction is catalyzed by cytochrome P-450, cytochrome b5 and NADPH-cytochrome c reductase. In microsomes, a decrease with age is generally observed in the cytochrome P-450 concentration and the NADPH-cytochrome c reductase activity, while there is no change in cytochrome b5. In addition, most microsomal drug-metabolizing enzymes decrease with age in male rats but not in females. The changes in enzyme activities in the male and female mouse are more complex. In fact, increases, decreases and no changes were found. Important phase II reactions are glutathione conjugation and glucuronidation; changes in both reactions with age seem to be of minor importance. Studies with hepatocytes isolated from male rats of different ages reveal that the monooxygenase system mediated metabolism of digitoxin and aflatoxin B1 decreases with age. It can be concluded that the observed decrease in the functional capacity of the monooxygenase system greatly determines the decrease in drug metabolism with age. However, it should always be kept in mind that, among others, the age-related changes in drug metabolism in rats are strongly sex dependent, which is not the case in man. Therefore, caution should be exercised in transferring these data to the human situation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6727439     DOI: 10.1016/0047-6374(84)90126-x

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  8 in total

1.  The effect of age on glucuronidation and sulphation of paracetamol by human liver fractions.

Authors:  B Herd; H Wynne; P Wright; O James; K Woodhouse
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

2.  The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis.

Authors:  D G Le Couteur; A J McLean
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

3.  Localized hepatocarcinogenesis: the response of the liver and kidney to implanted carcinogens.

Authors:  K Aterman
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

Review 4.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

5.  The kinetic basis for age-associated changes in quercetin and genistein glucuronidation by rat liver microsomes.

Authors:  Bradley W Bolling; Michael H Court; Jeffrey B Blumberg; C-Y Oliver Chen
Journal:  J Nutr Biochem       Date:  2009-05-14       Impact factor: 6.048

6.  Effect of sodium butyrate on primary cultures of adult rat hepatocytes.

Authors:  G L Engelmann; J L Staecker; A G Richardson
Journal:  In Vitro Cell Dev Biol       Date:  1987-02

7.  Age-dependent induction of preneoplastic liver cell foci by 2-acetylaminofluorene, phenobarbital and acetaminophen in F344 rats initially treated with diethylnitrosamine.

Authors:  R Hasegawa; S Takahashi; K Imaida; S Yamaguchi; T Shirai; N Ito
Journal:  Jpn J Cancer Res       Date:  1991-03

8.  [18F]Atorvastatin Pharmacokinetics and Biodistribution in Healthy Female and Male Rats.

Authors:  Gonçalo S Clemente; Inês F Antunes; Jürgen W A Sijbesma; Aren van Waarde; Adriaan A Lammertsma; Alexander Dömling; Philip H Elsinga
Journal:  Mol Pharm       Date:  2021-08-05       Impact factor: 4.939

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.